Skip to main content

Alex Trebek Says His Pancreatic Cancer Is ‘Near Remission’

Jeopardy! host Alex Trebek shocked the world in March when he announced he had been diagnosed with Stage IV pancreatic cancer. He shocked it again on Wednesday with a great report from his doctors.

Trebek tells People his physicians say he is “near remission” and some of the tumors have shrunk more than 50% after treatment.

“It’s kind of mind boggling,” says Trebek.

Pancreatic cancer is an especially deadly form of the disease. Just 3% of patients with stage IV pancreatic cancer are alive 5 years after being diagnosed, according to The American Cancer Society. (Stage IV means that, at the time of diagnosis, a cancer has already metastasized or spread, beyond the initial cancer.)

The 78-year-old host, though, says he is drawing strength from the support of friends and fans. He acknowledges he is not yet out of the woods and says he still has several more rounds of chemo to go through.

The symptoms of pancreatic cancer may include pain in the abdomen or back, weight loss, jaundice, nausea, pancreatitis, and/or recent-onset diabetes. More than 56,000 American are diagnosed with pancreatic cancer each year, according to the Pancreatic Cancer Action Network.

Trebek initially addressed the diagnosis on YouTube, which is becoming one of his go-to platforms to discuss health issues. In 2018, Trebek posted a video after a "slight medical problem." After a fall two months earlier, he had blood clots removed from his brain.

Listen and subscribe to our new audio briefing, Fortune 500 Daily:



from Fortune http://bit.ly/2Wvc2qs
Labels:

Comments

Post a Comment

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 bill...
Post a Comment
Read more

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected ma...
Post a Comment
Read more